---

---

sector : Professional, scientific, and technical services    tags : Vaccine   

save search

---

Global mRNA Vaccine Market Research Report 2023-2028: COVID-19 Success Opens New Avenues with with 444 Ongoing Clinical Studies Worldwide
Published: 2023-11-08 (Crawled : 03:00) - prnewswire.com
GLAXF | $20.2 -14.18% 510 |

Health Technology

| 17.03% | O: 1.91% H: 0.0% C: 0.0%
VERV | $6.64 -0.3% -0.3% 1.1M |

Professional, Scientific, and T...

| -63.96% | O: 0.37% H: 0.64% C: -10.76%
GSK | $39.75 1.22% 0.0% 1.6M |

Health Technology

| 13.21% | O: 0.46% H: 0.46% C: -0.23%
MRNA S | $101.44 -0.55% -0.55% 2.6M |

Health Technology

| 40.43% | O: -0.01% H: 0.03% C: -3.14%
CVAC | News | $2.44 0.0% 790K |

Health Technology

| -55.72% | O: 0.91% H: 1.08% C: -1.44%
BNTX | $86.82 0.75% 0.75% 1.6M |

Health Technology

| -15.82% | O: 0.13% H: 0.08% C: -2.81%
ARCT 4 | $25.995 -1.23% -1.25% 630K |

Health Technology

| 34.35% | O: -0.36% H: 0.79% C: -0.61%
covid-19 success report vaccine mrna worldwide ongoing research global market

---

Ault Alliance Announces Alzamend Neuro Has Initiated Its Phase I/IIA Trial for Its Immunotherapy Vaccine (ALZN002) to Treat Mild to Moderate Dementia of the Alzheimer’s Type
Published: 2023-04-04 (Crawled : 18:00) - biospace.com/
ALZN | $0.6894 -0.23% -0.23% 28K |

Professional, Scientific, and T...

| 40.82% | O: 2.04% H: 1.0% C: -0.5%
alzn002 vaccine alzheimer’s dementia immunotherapy trial initiated

---

Alzamend Neuro Announces the Initiation of a Phase I/IIA Trial for Its Immunotherapy Vaccine (ALZN002) to Treat Mild to Moderate Dementia of the Alzheimer’s Type
Published: 2023-04-03 (Crawled : 14:00) - biospace.com/
ALZN | $0.6894 -0.23% -0.23% 28K |

Professional, Scientific, and T...

| 62.35% | O: 3.53% H: 24.55% C: 11.36%
alzn002 vaccine alzheimer’s dementia immunotherapy trial

---

Global Vaccine Contract Manufacturing Market Report 2023: Favorable Patient Demographics and Growing Vaccinations of Newborns and Children Fuels Sector
Published: 2023-03-09 (Crawled : 00:00) - prnewswire.com
LZAGF | $563.5 -19.1% 6 |

Health Technology

| -1.01% | O: -0.04% H: 2.87% C: 0.54%
LZAGY | $55.65 0.02% 32K |

Professional, Scientific, and T...

| 0.35% | O: 0.72% H: 1.11% C: -0.37%
ICLR | $288.32 -1.2% -1.21% 640K |

Health Technology

| 31.78% | O: 0.83% H: 0.0% C: -4.27%
global report growing children vaccine contract favorable market

---

GreenLight Biosciences receives approval to initiate Phase I/II clinical trial of Covid-19 mRNA vaccine candidate
Published: 2023-02-01 (Crawled : 14:00) - biospace.com/
GRNA | $0.2995 -0.03% -0.07% 0 |

Professional, Scientific, and T...

| -72.52% | O: 6.24% H: 0.0% C: -5.87%
covid-19 candidate vaccine mrna trial approval

---

Alzamend Neuro Receives FDA “Study May Proceed” Letter for Phase I/IIA Trial Under Its Investigational New Drug Application for an Immunotherapy Vaccine (ALZN002) to Treat Mild to Moderate Dementia of the Alzheimer’s Type
Published: 2022-10-31 (Crawled : 15:00) - biospace.com/
ALZN | $0.6894 -0.23% -0.23% 28K |

Professional, Scientific, and T...

| -38.94% | O: 1.77% H: 6.09% C: 1.74%
alzn002 fda dementia drug immunotherapy vaccine application trial alzheimer’s

---

Alzamend Neuro Receives Positive Pre-IND Response from FDA for AL002, a Cell-Based Therapeutic Vaccine That Seeks to Restore the Ability of Patients’ Immunological System to Combat Alzheimer’s Disease
Published: 2022-01-12 (Crawled : 20:00) - alzamend.com
ALZN | $0.6894 -0.23% -0.23% 28K |

Professional, Scientific, and T...

| -62.5% | O: 0.54% H: 7.03% C: -0.54%
al002 alzheimer fda system disease cel positive pons vaccine alzheimer’s alzheimer's disease alzheimer's

---

Alzamend Neuro Announces Pre-IND Submission for AL002 as a Cell-Based Therapeutic Vaccine That Seeks to Restore the Ability of Patient’s Immunological System to Combat Alzheimer’s
Published: 2021-07-30 (Crawled : 11:00) - biospace.com/
ALZN | $0.6894 -0.23% -0.23% 28K |

Professional, Scientific, and T...

| -85.19% | O: -1.5% H: 0.0% C: 0.0%
alzheimer al002 vaccine submission cel alzheimer’s alzheimer's

---

ImmunoPrecise and LiteVax Advance SARS-CoV-2 Vaccine Candidate
Published: 2020-12-14 (Crawled : 15:00) - biospace.com/
IPA | $1.24 0.0% 150K |

Professional, Scientific, and T...

| -86.45% | O: 4.06% H: 14.26% C: 12.82%
vaccine sars-cov-2

---

Gainers vs Losers

67%

33%

Top 10 Gainers

AGBA | News | $1.26 215.0% 68.25% 130M |

Finance

EGOX | $0.0515 43.06% 30.1% 330M |

OLB 4 | $0.33 -14.95% 25.53% 840K |

Technology Services

NVFY | $2.77 31.28% 23.83% 33M |

Consumer Durables

ZCMD | $1.87 28.97% 22.46% 31M |

Commercial Services

RCON | $0.1112 13.01% 21.28% 1.7M |

Distribution Services

INSG | $3.03 25.21% 20.13% 330K |

Electronic Technology

GCTK | $0.8191 22.25% 18.2% 190K |

Manufacturing

WLGS | News | $0.59 18.0% 17.9% 2.3M |

ASNS | $0.828 21.75% 17.86% 18K |

---

Your saved searches

---